Although the hepatic metastasectomy scenario involves metastatic disease, because the patient is rendered disease-free by surgery one might view this as an adjuvant scenario. Taking this view, most oncologists and the faculty stop treatment after a defined number of cycles as is typical in the management of localized disease.

Cartwright T et al. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin Colorectal Cancer 2012;11(3):155-66. Abstract

Venook AP et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Proc ASCO 2014;Abstract LBA3.

Stein A, Schmoll JH. Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol 2013;5(3):193-203. Abstract